太突然！刚刚宣布：裁员9000人！

Core Viewpoint - The Danish weight loss drug giant Novo Nordisk announced a global layoff of 9,000 employees, representing 11% of its workforce, in response to increasing market competition and declining performance. The company aims to save 8 billion Danish kroner (approximately 9.3 billion RMB) by the end of 2026 [2][4]. Group 1: Layoff Announcement - Novo Nordisk's layoff plan will affect approximately 9,000 positions globally, including about 5,000 in Denmark, as part of a transformation initiative to simplify organizational structure and enhance decision-making speed [2][3][4]. - The layoffs are expected to primarily impact functional departments and headquarters roles, with the goal of reallocating resources to growth opportunities in diabetes and obesity treatment [4][5]. Group 2: Performance Guidance Adjustment - Novo Nordisk has lowered its performance guidance for the year, now expecting a 4% to 10% increase in operating profit at constant exchange rates, down from a previous forecast of 10% to 16% [2][6]. - The company anticipates a one-time restructuring cost of 8 billion Danish kroner, with a significant portion expected to impact the 2025 financial results [6]. Group 3: Market Competition - The global weight loss drug market is becoming increasingly competitive, with Novo Nordisk losing its leading position in the U.S. market to rival Eli Lilly [7][9]. - The introduction of cheaper generic versions of its GLP-1 drug, semaglutide, has contributed to a slowdown in growth, particularly in key markets like the U.S. [8][9].